. 2021 Feb 8;23(7):1139–1147. doi: 10.1093/neuonc/noab019
© The Author(s) 2021. Published by Oxford University Press on behalf of the Society for Neuro-Oncology. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com
This article is published and distributed under the terms of the Oxford University Press, Standard Journals Publication Model (https://academic.oup.com/journals/pages/open_access/funder_policies/chorus/standard_publication_model)
Fig. 3.
Classification of pretreatment growth rate depending on drug response classes.